Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

311
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
311
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

487
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
487
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

296
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
296
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

302
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
302
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

635
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
635
Inflammatory Bowel Disease V: Surgical Management01:21

Inflammatory Bowel Disease V: Surgical Management

302
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
302

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Clinical Utility of Precision-Guided Dosing for Adalimumab Therapy Optimization in Inflammatory Bowel Disease: A Clinical Experience Program.

Pharmaceutics·2025
Same author

The colitis may be microscopic, but the diarrhea is not: update on the treatment of microscopic colitis and immune checkpoint inhibitor colitis.

Current opinion in gastroenterology·2023
Same author

Nonsteroidal anti-inflammatory drug exposure and the risk of microscopic colitis.

BMC gastroenterology·2022
Same author

Polygenic risk score is a predictor of adenomatous polyps at screening colonoscopy.

BMC gastroenterology·2021
Same author

Microbiota-based Therapies Clostridioides difficile infection that is refractory to antibiotic therapy.

Translational research : the journal of laboratory and clinical medicine·2020
Same author

Fecal Microbiota Transplantation Is Highly Effective in Real-World Practice: Initial Results From the FMT National Registry.

Gastroenterology·2020
Same journal

GLP-1 Receptor Agonists and Hepatic Encephalopathy in Cirrhosis: A Protective Signal Requiring Cancer and Nutritional Phenotyping.

Journal of clinical gastroenterology·2026
Same journal

Endoscopic Incisional Therapy for Benign Esophageal Strictures: A Systematic Review and Meta-Analysis.

Journal of clinical gastroenterology·2026
Same journal

International Consensus Statements on the Use of Topical Endoscopic Hemostatic Powders in the Treatment of Acute Gastrointestinal Bleeding.

Journal of clinical gastroenterology·2026
Same journal

Do Risk Factors for Reflux Symptoms After Peroral Endoscopic Myotomy Necessarily Increase the Occurrence of Postoperative Gastroesophageal Reflux?

Journal of clinical gastroenterology·2026
Same journal

Subgroup Stratification by Regimen, Geography, and Population Is Necessary to Validate Nitazoxanide-based Helicobacter pylori Eradication Therapy.

Journal of clinical gastroenterology·2026
Same journal

The Impact of Glucagon-Like Peptide 1 Receptor Agonists Versus Diabetes Mellitus on Endoscopic Procedures: A Case-Control Study From a Large Tertiary Care Health System.

Journal of clinical gastroenterology·2026
See all related articles

Related Experiment Video

Updated: Nov 21, 2025

Using Multi-fluorinated Bile Acids and In Vivo Magnetic Resonance Imaging to Measure Bile Acid Transport
08:42

Using Multi-fluorinated Bile Acids and In Vivo Magnetic Resonance Imaging to Measure Bile Acid Transport

Published on: November 27, 2016

11.4K

Bile Acid Sequestrant Therapy in Microscopic Colitis.

Michael J Northcutt1, Nicole M Gentile, Jay L Goldstein

  • 1Division of Gastroenterology, University of Chicago Medicine, NorthShore University Health System, Evanston, IL.

Journal of Clinical Gastroenterology
|January 14, 2021
PubMed
Summary
This summary is machine-generated.

Bile acid sequestrants (BAS) show promise as a corticosteroid-sparing treatment for microscopic colitis (MC). This therapy may help reduce budesonide dependence and offers a potential alternative for managing this chronic diarrheal condition.

More Related Videos

Ileectomy-induced Bile Overaccumulation in Mouse Intestine
06:55

Ileectomy-induced Bile Overaccumulation in Mouse Intestine

Published on: August 21, 2017

9.8K
Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
08:34

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Published on: July 27, 2022

1.0K

Related Experiment Videos

Last Updated: Nov 21, 2025

Using Multi-fluorinated Bile Acids and In Vivo Magnetic Resonance Imaging to Measure Bile Acid Transport
08:42

Using Multi-fluorinated Bile Acids and In Vivo Magnetic Resonance Imaging to Measure Bile Acid Transport

Published on: November 27, 2016

11.4K
Ileectomy-induced Bile Overaccumulation in Mouse Intestine
06:55

Ileectomy-induced Bile Overaccumulation in Mouse Intestine

Published on: August 21, 2017

9.8K
Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
08:34

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Published on: July 27, 2022

1.0K

Area of Science:

  • Gastroenterology
  • Internal Medicine
  • Pharmacology

Background:

  • Microscopic colitis (MC) is a prevalent cause of chronic diarrhea.
  • Budesonide is effective for inducing remission but high relapse rates occur after treatment cessation.

Purpose of the Study:

  • To evaluate the efficacy of bile acid sequestrants (BAS) as a corticosteroid-sparing treatment for microscopic colitis (MC).

Main Methods:

  • Retrospective review of 79 patients with histology-confirmed MC from an institutional registry.
  • Assessment of BAS efficacy in budesonide-naive patients and as maintenance therapy in budesonide-dependent patients.

Main Results:

  • 76% of budesonide-naive patients responded to BAS.
  • 50% of budesonide-dependent patients reduced their budesonide dose, and 20% discontinued it completely while on BAS.
  • 15% of patients stopped BAS due to intolerance or lack of perceived benefit.

Conclusions:

  • Bile acid sequestrants (BAS) may serve as an effective corticosteroid-sparing agent for microscopic colitis (MC) management.
  • Consideration of BAS after budesonide induction is warranted.
  • Further controlled studies are necessary to confirm long-term efficacy and tolerability.